KALARIS THERAPEUTICS, INC. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
KALARIS THERAPEUTICS, INC. (KLRS) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of $867.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-11
- KALARIS THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was $747.00K.
- KALARIS THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was $120.00K.
- KALARIS THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was $1.73M, a 159.40% increase year-over-year.
- KALARIS THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was $1.22M.
- KALARIS THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was $2.14M, a 1764.35% increase from fiscal 2024.
- KALARIS THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was $115.00K.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $747.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $867.00K 10-Q · filed 2026-08-11 | $2.59M derived: sum of 3 quarters · filed 2026-08-11 | $3.82M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2026-03-31 | $120.00K 10-Q · filed 2026-05-12 | $1.84M derived: sum of 2 quarters · filed 2026-05-12 | $3.07M derived: sum of 3 quarters · filed 2026-05-12 | $2.27M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-12-31 | $1.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $2.95M derived: sum of 2 quarters · filed 2026-03-17 | $2.15M derived: sum of 3 quarters · filed 2026-08-11 | $2.14M 10-K · filed 2026-03-17 | ||
| 2025-09-30 | $1.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $427.00K derived: sum of 2 quarters · filed 2026-08-11 | $419.00K 10-Q · filed 2025-11-12 | $1.08M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-06-30 | -$797.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$805.00K 10-Q · filed 2026-08-11 | $268.00K 10-Q · filed 2025-08-13 | -$140.00K derived: sum of 3 quarters · filed 2026-08-11 | -$898.00K derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-03-31 | -$8.00K 10-Q · filed 2026-05-12 | $152.00K 10-Q · filed 2025-05-14 | $657.00K derived: sum of 2 quarters · filed 2026-05-12 | -$101.00K derived: sum of 3 quarters · filed 2026-05-12 | $33.00K derived: sum of 4 quarters · filed 2026-05-12 | |
| 2024-12-31 | $665.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$93.00K derived: sum of 2 quarters · filed 2026-03-17 | $41.00K derived: sum of 3 quarters · filed 2026-03-17 | $115.00K 10-K · filed 2026-03-17 | ||
| 2024-09-30 | -$758.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$624.00K derived: sum of 2 quarters · filed 2025-11-12 | -$550.00K 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | $134.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $208.00K 10-Q · filed 2025-08-13 | ||||
| 2024-03-31 | $74.00K 10-Q · filed 2025-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |